Investigating Correlates of Fatigue in Cancer Patients receiving Treatment

研究接受治疗的癌症患者疲劳的相关性

• 批准号: 8554731
• 负责人: Leorey Saligan
• 金额: $ 8.37万
• 依托单位: NATIONAL INSTITUTE OF NURSING RESEARCH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8554731
• 关键词: Affective; Behavioral; Biological Markers; Blood specimen; Cancer Patient; Clinic; Cognitive; Data; Dimensions; Disease; Emotional; Energy Metabolism; Enrollment; Etiology; Fatigue; Gene Expression; IL8 gene; Immunotherapy; Individual; Inflammatory; Insulin-Like Growth Factor I; Interleukin-6; Intervention; Life Experience; Longitudinal Studies; Malignant neoplasm of prostate; Measures; Mental Depression; Molecular; Molecular Genetics; National Cancer Institute; Observational Study; Participant; Patient Recruitments; Patient Self-Report; Patients; Physiological; Protocols documentation; Provider; Psyche structure; Research Personnel; Risk; Risk Factors; Sensory; Skeletal Muscle; Symptoms; TNF gene; Time Study; Tissue Sample; Treatment-Related Cancer; Work; cancer therapy; chemotherapy; cognitive function; cytokine; experience; health related quality of life; hormone therapy; improved; interest; multidisciplinary; muscle strength; peripheral blood; prospective; risk benefit ratio

The study has accrued 29 participants since the start of enrolment. Eleven of 29 subjects were accrued since last review, and 17 patients completed all the study time points, 6 are actively enrolled. Recruitment was conducted by self-referral, referrals from other National Cancer Institute providers, and/or from the Patient Recruitment and Public Liaison Office. The PI is working closely with collaborators from the Multidisciplinary Prostate Cancer Clinics of the National Cancer Institute to improve recruitment of interested individuals. There is an increased inquiry from both patients and investigators from NCI about the protocol. No treatment or intervention is offered in this protocol and the risk: benefit ratio remains the same.

自入组开始以来，该研究已累积了29名参与者。自上次审查以来，29例受试者中有11例入组，17例患者完成了所有研究时间点，6例正在积极入组。招募是通过自我推荐，从其他国家癌症研究所提供者，和/或从病人招募和公共联络办公室转介。PI正在与国家癌症研究所多学科前列腺癌诊所的合作者密切合作，以改善感兴趣的个人的招募。NCI的患者和研究者对该方案的询问越来越多。本方案未提供治疗或干预，风险：受益比保持不变。